Background: Cancer progression and non-cancer-related morbidities can affect the quality of life and survival of patients with head and neck squamous cell carcinomas (HNSCC). The aim of this study was to investigate the risk factors for the development of non-cancer health events (NCHEs) in HNSCC.
introduction Worldwide, more than half a million new cases of head and neck cancer are diagnosed each year [1] . Traditional approaches to the management of head and neck cancer have been modified by a greater understanding of underlying disease mechanisms and efforts to reduce treatment-related complications. Multimodality therapy including surgery, chemotherapy, and radiotherapy (RT) has become the standard treatment [2] [3] [4] . Recently, the human papilloma virus (HPV) was identified as a cause of oropharyngeal cancer, particularly in nonsmokers, with an increasing incidence in cancer patients [5] [6] . HPV-positive cancer patients have a better prognosis than HPV-negative cancer patients [7] . However, the overall survival rates for head and neck cancer have not changed substantially over the last three decades despite diagnostic and therapeutic advances [2] , which may suggest other potential factors affecting patient survival outcomes.
Non-cancer factors related issues have been suggested as major causes of mortality in patients with head and neck cancer [8] [9] [10] . Patients with head and neck squamous cell carcinoma (HNSCC) are at risk of a variety of non-cancerassociated (competing) causes of mortality, as well as cancerspecific causes such as disease progression or secondary cancers [10] . Non-cancer mortality has a 5-year cumulative incidence of 23.8% [8] [9] [10] and appears to be associated with several demographic and health status characteristics, such as female gender, increasing age, an increasing comorbidity index, high body mass index (BMI), and a longer distance traveled to the treating center, rather than with the index of secondary cancer characteristics [8] . Additionally, second primary cancers (SPC) can affect patient survival, with an overall reported incidence of 19% [8] [9] [10] [11] [12] .
Patients with head and neck cancer can develop non-cancerassociated morbidities requiring readmission after cancer treatment, which can potentially lead to non-cancer-associated mortality. Hospital admissions from unexpected non-cancerassociated morbidities can increase the total medical costs and decrease the patient's quality of life. Therefore, identifying factors that are predictive of non-cancer-associated morbidities may help to minimize the incidence of non-cancer-associated mortality. Although the incidence and risk factors for noncancer-associated mortalities in patients with head and neck cancer are well characterized [8] [9] [10] , very limited data are available on the risk of non-cancer-associated morbidities in patients requiring hospital admission. Therefore, we sought to evaluate the incidence of predictive factors for non-cancer health events (NCHEs), including non-cancer-associated causes of morbidity and mortality, in patients with HNSCC.
patients and methods

study population
Between 2005 and 2009, we identified 733 patients from the hospital cancer registry who underwent treatment for head and neck cancer at the Asan Medical Center, a tertiary referral hospital. We included patients who had (i) pathologically proven SCC, (ii) newly-diagnosed head and neck cancer with no previous history of treatments, and (iii) primary tumor sites in the oral cavity, oropharynx, larynx, and/or hypopharynx. We excluded patients who (i) had non-metastatic carcinoma in situ or other pathologies, (ii) had primary tumor(s) arising in the sinonasal area, or unknown sites, (iii) had distant metastasis at initial presentation, and/or (iv) were survivors lost to follow-up within 1 year of diagnosis. Finally, 465 patients were eligible for this study (Figure 1 ). This study was approved by the institutional review board of the Asan Medical Center and informed consent was waived.
treatments
The primary tumors were excised with ≥1 cm adequate resection margins if feasible. The modified radical or radical neck dissection (ND) from level I to V was carried out in patients with clinically node-positive diseases. Adjuvant RT with/without chemotherapy was considered in patients carrying unfavorable risk factors, based on tumor board discussions on oncological safety. Postoperative RT was commonly started within 4-8 weeks after completion of surgery. Radiation was administered in a daily fraction of 1.8 or 2.0 Gy on 5 days each week. The total radiation dose was 44-50 Gy with an additional boost dose of 10-15 Gy delivered to the tumor beds and/or residual diseases (supplementary Table S1 , available at Annals of Oncology online). . IC was followed by concurrent chemoradiotherapy (CRT) or RT. RT, consisting of intensity-modulated or three-dimensional conformal radiation, was started within 6 weeks after the last cycle of IC. Radiation was administered in daily fractions of 1.8 or 2.0 Gy on 5 days each week for 8 weeks. The total radiation dose for all patients was 57-80 Gy. Concurrent chemotherapy consisted of high-dose cisplatin (75-100 mg/m 2 ), infused on days 1, 22, and 43. Salvagy surgery was used for patients with disease progression on the primary site after IC or residual diseases on the primary site or neck after CRT. The initial treatments were summarized in supplementary Table S1 , available at Annals of Oncology online.
follow-up
All patients received physical and endoscopic examinations at every visit after the completion of initial treatments. The patients were evaluated every 1 to 3 months in the first year, every 2 to 4 months in the second and third year, 6 months in the fourth and fifth year, and annually thereafter. Routine computed tomography (CT)/magnetic resonance imaging (MRI) of the head and neck and whole-body screening with 18 Ffluorodeoxyglucose (FDG) positron emission tomography (PET)/CT was carried out every 6-12 months in the second year after treatments. Thereafter, the CT/MRI and FDG PET/CT were alternatively checked annually. If there was clinical suspicion of remnant, recurrent or newly developed malignant lesions, one or more diagnostic modalities and biopsies were utilized to confirm these lesions. The patients who had trouble symptoms or medical problems initiated extra visits and whether to be hospitalized was decided by the treating physicians.
definition of non-cancer health event
Non-cancer-associated morbidity was defined as admission to the hospital after treatment for any cause not directly related to cancer, or newly developed SPC. Events resulting in (i) emergency room visits not resulting in hospital admission or (ii) admissions for diagnostic evaluation were not included. Events were recorded from the end date of initial treatment until the last follow-up date. We analyzed the causes and incidence of posttreatment non-cancer-associated morbidities. We did not consider any treatment-related morbidity requiring prolonged hospitalization during the initial treatment of HNSCC. We did, however, quantify the incidence of non-cancer-related morbidities requiring admission during treatment of recurrent tumors. Non-cancer-associated mortality was defined as death from any cause bearing no definite relation to cancer or SPC [8, 9] . Causes of death were determined using clinical data, phone calls to patients' families, and/or national databases. A NCHE was defined as the initial occurrence of either non-cancer-associated morbidity or mortality.
variables All patients were evaluated for age, gender, site of the primary tumor, and tumor-node-metastasis (TNM) stage of the primary tumor, underlying comorbidities, smoking status, alcohol consumption, initial BMI (kg/m 2 ), educational level, residence, and treatment modalities from medical records. One drink was defined as 15.6 mL of pure ethanol (100%) [13] . Co-existing morbidity was categorized according to the Charlson Figure 1 . Flow chart of the study population.
original articles Annals of Oncology
Comorbidity Index (CCI) [14] . The CCI weighting was selected before data analysis. The index cancer at initial diagnosis and previously developed non-metastatic SPC was assigned as the weight of 0 and 2, respectively [8, 14] . If the previous SPC was diagnosed at >5 years ago, the SPC was considered as a weight of 0. Age (≥60 versus <60 years), sex (male versus female), BMI (≥20 versus <20), alcohol use (>1 versus 0-1 drink per day), residence (urban versus rural), education (≥ or <high school), CCI (≥1 versus 0), site of primary tumor (the larynx and hypopharynx versus others), overall TNM stage (I/II versus III/IV), and type of initial treatments (surgery versus non-surgery) were dichotomized. The patients who were aimed to undergo surgery as an initial treatment were allocated to the surgery group, whereas those who were initially considered with non-surgical treatments were allocated to the non-surgical group.
statistical analysis
The Kaplan-Meier method for estimating cumulative event probabilities may be problematic when competing risks are present [15] . The method often results in an overestimate of the cumulative incidences in the presence of competing risks. Therefore, the cumulative incidence of locoregional and distant failures, SPC, cancer-associated mortality, and non-cancer-associated mortality were calculated using cumulative incidence functions [16] . Time to events was from the end day of the initial treatments to the first occurrence of events. A competing risk regression model was used to identify predictors of NCHEs, and the estimated hazard ratio (HR) and 95% confidence interval (CI) were calculated. Covariates were selected based on previously published analyses and variables of P < 0.05 in univariate analysis [8, 9] . Statistical analyses were conducted using SAS 9.2 (SAS Institute Inc.) and R version 2.14.1 (R Project for Statistical Computing, http://www.r-project.org) and package 'cmprsk' in R was used. A two-sided P value of <0.05 was considered statistically significant.
results
patient characteristics
Eligible patients comprised 369 men and 86 women with a median age of 60 years (range, 20-80 years). The characteristics of the study population are summarized in Table 1 . The most common site of primary tumor was the larynx (48.2%), followed by the oral cavity (26.0%), oropharynx (17.4%), hypopharynx (3.7%), and nasopharynx (1.1%). From the overall population, 126 patients (27.1%) had comorbidities with a CCI of ≥1, 150 patients (32.3%) had locally advanced primary tumors (T3 or T4), 170 patients (36.6%) had positive nodal disease, and 234 patients (50.3%) were in the advanced stages (III or IV). In addition, 346 patients (74.4%) were treated by surgery combined with/ without chemotherapy and/or RT. The median follow-up period was 47.6 months (range, 1.2-86.5 months).
second primary cancers and non-cancer health events
Of the 465 patients, 91 (19.6%) and 35 (7.5%) patients had locoregional and distant metastasis, respectively. The 4-year cumulative incidence of locoregional and distant failures were 19.5% (95% CI, 15.8-23.2%) and 6.5% (4.2-8.8%), respectively. The 4-year cumulative incidence of cancer events (first occurrence of locoregional or distant failure) was 22.4% (18.5-26.3%) (Figure 2a ). In addition, 49 patients (10.5%) developed new SPCs at or after the diagnosis of HNSCC, with a 4-year cumulative SPC incidence of 10.0% (7.1-13.0%). One patient developed simultaneous SPCs of the tongue and esophagus. The most common site of newly developed SPC was the lung (26.0%), followed by the stomach (16.0%), colon (14.0%), and head and neck (8.0%). Thirty-three patients (7.1%) had a previous history of SPC. The most common site of prior SPC was the stomach (30.6%), followed by the liver (16.7%), lung (13.9%), and head and neck (13.9%). The overall incidence of SPC in the study population was 16.8%, and the overall most common site of SPC (new or previous) was the stomach (22.1%), lung (20.1%), head and neck (10.5%), and liver (10.5%). The incidences of SPCs are listed in Table 2 .
Eighty-five mortalities were observed: cancer-associated mortalities in 50 patients, SPC-associated mortalities in 10 patients, and non-cancer-associated mortalities in 25 patients. Of all the study patients, the 4-year cumulative incidence of mortality from HNSCC, SPC, and non-cancer-causes was 11.2% (95% CI, 8.2-14.2%), 2.2% (0.8-3.6%), and 4.7% (2.7-6.7%), respectively (Figure 2b) .
Eighty-three patients (17.8%) suffered from non-cancerassociated morbidities (Table 3) , of which 16 (19.3%) experienced multiple morbidities: two events in 10 patients, three events in five patients, and five events in one patient. Of 16 patients with multiple morbidities, 10 experienced the same kinds of events with previous morbidities and six experienced AJCC, American Joint Committee on Cancer (6th edition); TNM, tumornode-metastasis.
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the different kinds of events. The most common causes of noncancer-associated morbidities were respiratory diseases including pneumonia (24.1%) and other respiratory diseases (13.3%), followed by treatment-related complications (22.8%), gastrointestinal diseases (10.8%), cerebrovascular diseases (8.4%), and cardiac diseases (8.4%). The causes of non-cancerassociated mortalities were similar to those of non-cancerassociated morbidities, of which respiratory diseases (36.0%) were most frequent. Of the 25 non-cancer-associated mortalities, 12 (48.0%) experienced non-cancer-associated morbidities before death.
The remaining 13 (52%) died without any prior non-cancerassociated morbidity events. The 4-year cumulative incidence of NCHEs was 18.9% (95% CI, 15.1-22.7%) (Figure 2a ). One patient with a history of stomach cancer had newly developed lung cancer during the follow-up period. original articles
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The causes of non-cancer-associated morbidities and mortalities are summarized in Table 3 .
risk factors for non-cancer health events
Univariate analyses revealed that age ≥ 60, BMI < 20, rural residence, CCI ≥ 1, primary tumor site (the larynx or hypopharynx), non-surgical treatment, and stage III/IV disease were significantly associated with the occurrence of NCHEs (P ≤ 0.02; Table 4 ). Multivariate analysis showed that CCI ≥ 1 (P < 0.001; HR = 3.34, 95% CI = 2.14-5.20) and stage III/IV disease (P < 0.001; HR = 2.43; 95% CI = 1.54-2.83) were independent predictors of NCHEs.
discussion
Comorbidity can impact patient survival, which can lead to the development of non-cancer-associated competing mortality [17] . Our study on 465 patients revealed that non-cancerassociated morbidity and mortality occurred in 83 patients (17.8%) and 25 patients (5.4%), respectively, less than the rates reported in recent studies [8] [9] [10] . This discrepancy may be due to different study populations and ethnic groups. Our study consisted of the Asian patients, a single-ethnic group residing in the South Korea and all early to advanced stages. Majority (73%) of the patients were in good performance status of CCI 0. The incidence of non-cancer-associated mortality tends to steadily increase with increasing follow-up period after cancer treatment. The trend and incidence of all mortalities and noncancer-associated mortalities were similar to that in previous studies [8] [9] [10] . Of all deaths, ∼29% were not related to cancer progression. The pattern of non-cancer-associated morbidities and mortalities was similar in our data. Approximately 50% of patients with non-cancer-associated mortalities had a previous history of admission due to non-cancer causes before the diagnosis of head and neck cancer. A review of the data on health status and/or previous patient records may allow us to detect previous NCHEs and to reduce the incidence of noncancer-associated mortality.
We observed that the overall incidence of SPC was 16.8%, similar to that in previous studies [12, 18] . The most common site of SPC was the aero-digestive tract including the lung, stomach, head and neck, colon, and esophagus. The risk of SPC in patients with HNSCC is characterized by field cancerization, which is the development of multiple synchronous and metachronous tumors after carcinogenic insult in the aero-digestive tract [19] . The incidences of SPC in the stomach and liver were higher than those in western reports [12, 18] . This may be explained by geographic variations in the incidence of gastric cancer and hepatocellular carcinoma [1] . The high prevalence of H. pylori infection [20] and a high-salt-intake [21] in East Asia may be responsible for the differences in SPC incidence. In addition, the high prevalence of chronic hepatitis infection may lead to a high incidence of hepatocellular carcinoma, as chronic irritation due to the hepatitis virus is a well-known cause of hepatocellular carcinoma [22] . Careful surveillance of the chest and the gastroesophagus in HNSCC patients, in addition to the liver in hepatitis carriers, may be useful for detecting early SPC, thereby potentially increasing overall survival.
The occurrence of NCHEs was independently associated with CCI ≥ 1 and stage III/IV disease. Increasing use of multimodal chemoradiotherapy in patients with advanced disease may increase the risk of non-cancer-related health events, although intensive treatment of HNSCC may contribute to disease-free and overall survival [2, 8, 10, 23, 24] . We did not consider treatment-related complications during initial treatment. However, patients were continuously at risk of treatment-related complications such as aspiration, wound infection, RT-induced airway edema, and radionecrosis after the completion of cancer treatment. In the present study, increasing age, lower BMI (<20), rural residence, and nonsurgical treatment strategies were associated with the occurrence of NCHEs, but were not significant independent factors for occurrence. These findings differed from the results of previous studies [8, 9] , which reported that non-cancerassociated mortality was associated with female gender, increasing age, and a high BMI, in addition to an increasing comorbidity index. The discrepancy between the results of present and previous studies may result from the use of different end-points (NCHEs redefined from competing mortality). The differences in study population, treatment modalities, and follow-up may also affect the results. In addition, the multivariate model of our study population may still be underpowered to detect smaller effect sizes. Further prospective studies focusing on this issue in HNSCC patients will be required. Our study has several limitations, including those inherent in a retrospective study design. Nonetheless, we have systematically evaluated the causes of NCHEs and SPC in a relatively large cohort of HNSCC patients. Second, we analyzed the risk factors, including socioeconomic factors, individual health history, and cancer characteristics, of these patients for NCHEs. Analyzing the risk factors for NCHEs may guide physicians treating HNSCC patients.
In conclusion, our study showed that patients with HNSCC are at risk of NCHEs. The occurrence of NCHEs is associated with patient comorbidities and cancer characteristics. Because NCHEs are sometimes life-threatening, every effort should be made to avoid unexpected non-cancer-associated mortality, especially in HNSCC patients.
